Investment gaps in antimicrobial resistance research & development: trends in Europe, 2017–2021

Elisa Fabbro (), Usha Lamichhane (), Ralf Sudbrak (), Lesley Ogilvie (), Antonio Vitiello (), Andrea Zovi () and Michela Sabbatucci ()
Additional contact information
Elisa Fabbro: Area Science Park
Usha Lamichhane: Global AMR R&D Hub
Ralf Sudbrak: Global AMR R&D Hub
Lesley Ogilvie: Global AMR R&D Hub
Antonio Vitiello: Ministry of Health
Andrea Zovi: Ministry of Health
Michela Sabbatucci: National Institute of Health

The European Journal of Health Economics, 2025, vol. 26, issue 9, No 6, 1597-1611

Abstract: Abstract Introduction Antimicrobial resistance (AMR) remains one of the world’s most pressing health, economic, and social challenges. To combat this crisis, innovative tools have been developed to enhance research and development (R&D) efforts like the Global AMR R&D Hub's Dynamic Dashboard. By aggregating data from projects worldwide, the Dynamic Dashboard highlights trends and gaps in AMR R&D investments, totalling more than 8.22 billion Euros in the period 2017–2021 across the One Health continuum – human, animal, plant and environment. Launched in March 2020, the Dynamic Dashboard supports global priority setting and decision-making in AMR research, fostering strategic planning to promote efficient use of international resources and cross sectoral collaboration in AMR R&D. Methods Recognizing the urgent need for innovative diagnostics, treatments, and prevention strategies against AMR, here we presented a comprehensive analysis of public and philanthropic investments in AMR R&D obtained from January 2017 to December 2021 across Europe. Results We calculated the investments by One Health sector, year of funding, gross domestic product (GDP), research area, type of project, and infectious agent to raise awareness and promote global visibility of the R&D landscape in Europe. Our analysis revealed limited AMR R&D investments in the non-human sectors and non-bacterial topics, geographical polarization of funders, and some unaligned trends between the amount of investments and number of projects funded over the study period. Discussion Harnessing these data-driven insights, we aimed to inform stakeholders and optimize the allocation of economic resources for AMR R&D. Prioritizing unmet needs with the greatest potential for impact in this field will expedite the development of effective solutions to mitigate the global threat of AMR.

Keywords: Investments; R&D; Antimicrobial-resistance; AMR; Europe; Dynamic Dashboard; Global AMR R&D Hub (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-025-01796-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:26:y:2025:i:9:d:10.1007_s10198-025-01796-1

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-025-01796-1

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().